Development and Pilot Testing of an Assessment Tool for Performance of Anatomic Lung Resection.

CONCLUSIONS: TCAT-ARC demonstrated early evidence of validity and reliability in assessing performance of anatomic lung resection. The instrument may be most useful early in training and as a means for providing fine-grained formative feedback about which steps have been mastered and which still require improvement. TCAT-ARC may be employed in training programs to aid in the development of trainees' competency and as a part of an aggregate assessment of trainees' overall mastery of the procedure and readiness for independent practice. PMID: 31706874 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research

Related Links:

British Journal of Cancer, Published online: 18 February 2020; doi:10.1038/s41416-020-0756-3Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Non-small Cell Lung Cancer Stage I Intervention:   Combination Product: nivolumab Sponsor:   Hospital Israelita Albert Einstein Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Prescription Drug User Fee Act (PDUFA) date set for August 16, 2020. MADRID and DUBLIN, Feb. 17, 2020 -- (Healthcare Sales &Marketing Network) -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Admi... Biopharmaceuticals, Oncology, FDA Jazz Pharmaceuticals, PharmaMar , lurbinectedin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
(University of Texas M. D. Anderson Cancer Center) A study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within small cell lung cancer, leading to the evolution of multiple resistance mechanisms.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30 –40% of patients still show limited response. ...
Source: Clinical and Translational Medicine - Category: Internal Medicine Authors: Tags: Research Source Type: research
Authors: Chang CP, Hu MH, Hsiao YP, Wang YC Abstract Suppression of tumorigenicity 2 (ST2), also known as interleukin-1 receptor-like 1 (IL1RL1), is one of the natural receptors of IL-33. Three major isoforms, ST2L (transmembrane form), sST2 (soluble form), and ST2V, are generated by alternative splicing. Damage to stromal cells induces necrosis and release of IL-33, which binds to heterodimeric ST2L/IL-1RAcP complex on the membrane of a variety of immune cells. This IL-33/ST2L signal induces transcription of the downstream inflammatory and anti-inflammatory genes by activating diverse intracellular kinases and fac...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Conroy MJ, Lysaght J Abstract CX3CL1 (Fractalkine) is a multifunctional inflammatory chemokine with a single receptor CX3CR1. The biological effects elicited by CX3CL1 on surrounding cells vary depending on a number of factors including its structure, the expression pattern of CX3CR1, and the cell type. For instance, the transmembrane form of CX3CL1 primarily serves as an adhesion molecule, but when cleaved to a soluble form, CX3CL1 predominantly functions as a chemotactic cytokine (Fig. 1.1). However, the biological functions of CX3CL1 also extend to immune cell survival and retention. The pro-inflammator...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Acta Pharmacologica Sinica, Published online: 17 February 2020; doi:10.1038/s41401-019-0351-4Chalcomoracin inhibits cell proliferation and increases sensitivity to radiotherapy in human non-small cell lung cancer cells via inducing endoplasmic reticulum stress-mediated paraptosis
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Source Type: research
ConclusionsAntiangiogenic agents can achieve therapeutic benefit in advanced NSCLC patients and the combination of chemotherapy, targeted therapy or immunotherapy can lead to synergistic effect. However, exploring the best combination therapy and efficacy-related biomarkers needs further study.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
.
Source: Psychology, Health and Medicine - Category: International Medicine & Public Health Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Education | Lung Cancer | Science | Study | Training | Universities & Medical Training | USA Health